However, the use of HER-2 peptide-loaded IL-12-secreting dendritic cells (DC) for neoadjuvant vaccination against early breast cancer (DCIS; ductal carcinoma in situ) has led to complete pathological responses (pCR; i.e., no remaining disease) in up to 30% of immunized subjects [3,4,5,6]. The gene discussed is ERBB2; the disease is breast cancer.